Morgan Stanley’s Translate Bio, Inc. Common Stock TBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-698,131
| Closed | -$19.2M | – | 8188 |
|
|
2021
Q2 | $19.2M | Buy |
698,131
+354,602
| +103% | +$6.97M | ﹤0.01% | 2194 |
|
|
2021
Q1 | $5.67M | Buy |
343,529
+173,376
| +102% | +$3.95M | ﹤0.01% | 3281 |
|
|
2020
Q4 | $3.13M | Buy |
170,153
+34,803
| +26% | +$623K | ﹤0.01% | 3771 |
|
|
2020
Q3 | $1.84M | Buy |
135,350
+91,084
| +206% | +$1.4M | ﹤0.01% | 3725 |
|
|
2020
Q2 | $793K | Buy |
44,266
+14,810
| +50% | +$223K | ﹤0.01% | 4337 |
|
|
2020
Q1 | $294K | Sell |
29,456
-36,633
| -55% | -$300K | ﹤0.01% | 4692 |
|
|
2019
Q4 | $538K | Buy |
66,089
+55,842
| +545% | +$515K | ﹤0.01% | 4890 |
|
|
2019
Q3 | $102K | Buy |
10,247
+9,842
| +2,430% | +$92.9K | ﹤0.01% | 5443 |
|
|
2019
Q2 | $5K | Sell |
405
-4,303
| -91% | -$45.4K | ﹤0.01% | 6329 |
|
|
2019
Q1 | $48K | Sell |
4,708
-10,670
| -69% | -$81.8K | ﹤0.01% | 5687 |
|
|
2018
Q4 | $115K | Sell |
15,378
-179
| -1% | -$1.31K | ﹤0.01% | 5500 |
|
|
2018
Q3 | $156K | Buy |
+15,557
| New | +$181K | ﹤0.01% | 5547 |
|
Morgan Stanley's TBIO Position: Q3 2021 in Review
Morgan Stanley sold out of Translate Bio, Inc. Common Stock (TBIO) in Q3 2021, closing a stake of 698,131 shares — an estimated $19.2M sold.
Morgan Stanley first reported a position in TBIO in Q3 2018 and held it in 12 quarters. The position peaked at $19.2M in Q2 2021. 0 funds tracked by Wall St. Rank hold TBIO as of Q3 2021.
- Morgan Stanley reported no remaining Translate Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
- Morgan Stanley sold 698,131 Translate Bio, Inc. Common Stock shares in Q3 2021, an estimated $19.2M.
- Morgan Stanley first reported a position in Translate Bio, Inc. Common Stock in Q3 2018 and held it in 12 quarters.
- Morgan Stanley's Translate Bio, Inc. Common Stock position peaked at $19.2M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q3 2021.
Based on Morgan Stanley's 13F filing for Q3 2021, filed 15 Nov 2021.